IPSC

Century Therapeutics, Inc. [IPSC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IPSC Stock Summary

Top 10 Correlated ETFs

IPSC


Top 10 Correlated Stocks

IPSC


In the News

12:02 10 Dec 2023 IPSC

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

07:30 10 Dec 2023 IPSC

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.

10:40 10 Dec 2023 IPSC

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences:

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences in February:

04:03 10 Dec 2023 IPSC

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

10:59 10 Dec 2023 IPSC

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

11:18 10 Dec 2023 IPSC

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

IPSC Financial details

Company Rating
Buy
Market Cap
142.41M
Income
-128.96M
Revenue
2.49M
Book val./share
3.69
Cash/share
2.85
Dividend
-
Dividend %
-
Employees
163
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-1.1
Forward P/E
-1.22
PEG
0.42
P/S
57.24
P/B
0.65
P/C
0.84
P/FCF
-1.37
Quick Ratio
8.38
Current Ratio
8.5
Debt / Equity
0.22
LT Debt / Equity
0.21
-
-
EPS (TTM)
-2.19
EPS next Y
-1.95
EPS next Q
-0.51
EPS this Y
-23.31%
EPS next Y
-10.96%
EPS next 5Y
-34.25%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
49.49%
EPS Q/Q
-1.79%
-
-
-
-
SMA20
12.18%
SMA50
-17.06%
SMA100
-42.05%
Inst Own
26.14%
Inst Trans
0.79%
ROA
-32%
ROE
-49%
ROC
-0.36%
Gross Margin
100%
Oper. Margin
-5470%
Profit Margin
-5183%
Payout
-
Shs Outstand
59.84M
Shs Float
24.24M
-
-
-
-
Target Price
21.25
52W Range
1.28-9.705
52W High
-73.56%
52W Low
+138%
RSI
77.2
Rel Volume
1.2
Avg Volume
147.97K
Volume
177.96K
Perf Week
67.61%
Perf Month
61.9%
Perf Quarter
-31.41%
Perf Half Y
-29.59%
-
-
-
-
Beta
0.668
-
-
Volatility
0.4%, 0.28%
Prev Close
2.15%
Price
2.38
Change
8.68%

IPSC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000.09
Net income per share
-5.91-1.31-2.96-2.27
Operating cash flow per share
-0.39-0.99-2.750.24
Free cash flow per share
-0.45-1.22-4.14-0.29
Cash per share
1.961.816.885.46
Book value per share
-2.21-2.5512.235.24
Tangible book value per share
-2.21-2.7712.235.24
Share holders equity per share
-2.21-2.5512.235.24
Interest debt per share
00.520.810.87
Market cap
949.92M954.38M513.75M296.29M
Enterprise value
905.86M948.72M480.76M261.44M
P/E ratio
-3.86-17.46-5.36-2.26
Price to sales ratio
00056.99
POCF ratio
-58.75-23.13-5.7721.09
PFCF ratio
-50.99-18.68-3.83-17.9
P/B Ratio
-10.34-8.971.30.98
PTB ratio
-10.34-8.971.30.98
EV to sales
00050.29
Enterprise value over EBITDA
-48.77-20.16-5.09-2.16
EV to operating cash flow
-56.03-22.99-5.418.6
EV to free cash flow
-48.63-18.57-3.59-15.79
Earnings yield
-0.26-0.06-0.19-0.44
Free cash flow yield
-0.02-0.05-0.26-0.06
Debt to equity
0-0.20.060.16
Debt to assets
00.20.060.1
Net debt to EBITDA
2.370.120.350.29
Current ratio
28.16.5114.5710.72
Interest coverage
0-141.46-74.42-121.11
Income quality
0.070.770.93-0.11
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0006.13
Research and developement to revenue
00020.61
Intangibles to total assets
00.0900
Capex to operating cash flow
0.150.240.51-2.18
Capex to revenue
000-5.89
Capex to depreciation
-9.88-7.01-12-3.63
Stock based compensation to revenue
0002.05
Graham number
17.148.6528.5316.35
ROIC
2.690.75-0.22-0.34
Return on tangible assets
-2.71-0.56-0.22-0.27
Graham Net
-2.4-3.255.612.29
Working capital
81.13M66.69M212.5M289.9M
Tangible asset value
-91.86M-115.8M396.24M302.74M
Net current asset value
-98.63M-134.39M187.02M135.92M
Invested capital
0-0.20.060.16
Average receivables
0515.5K579K515K
Average payables
04.82M7.84M6.53M
Average inventory
02.11M815K-125K
Days sales outstanding
00054.76
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0006.67
Payables turnover
0000
Inventory turnover
0000
ROE
2.680.51-0.24-0.43
Capex per share
-0.06-0.24-1.39-0.53

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.040.010.0300
Net income per share
-0.53-0.55-0.53-0.56-0.55
Operating cash flow per share
-0.42-0.4-0.5-0.32-0.23
Free cash flow per share
-0.59-0.51-0.58-0.4-0.28
Cash per share
6.145.464.292.642.85
Book value per share
5.75.244.734.183.69
Tangible book value per share
5.75.244.734.183.69
Share holders equity per share
5.75.244.734.183.69
Interest debt per share
0.820.860.880.710.8
Market cap
573.36M296.29M203.38M187.23M118.9M
Enterprise value
509.28M261.44M168.01M164.81M109.12M
P/E ratio
-4.66-2.34-1.63-1.41-0.91
Price to sales ratio
257.81568.69118.241.89K803.35
POCF ratio
-23.65-12.93-6.96-9.73-8.71
PFCF ratio
-16.84-10.16-5.94-7.88-7.03
P/B Ratio
1.740.980.730.760.54
PTB ratio
1.740.980.730.760.54
EV to sales
228.99501.897.681.66K737.33
Enterprise value over EBITDA
-18.42-9.18-5.67-6.66-3.88
EV to operating cash flow
-21.01-11.41-5.75-8.56-8
EV to free cash flow
-14.96-8.96-4.91-6.94-6.45
Earnings yield
-0.05-0.11-0.15-0.18-0.28
Free cash flow yield
-0.06-0.1-0.17-0.13-0.14
Debt to equity
0.140.160.190.170.22
Debt to assets
0.090.10.110.10.12
Net debt to EBITDA
2.321.221.190.910.35
Current ratio
13.4410.729.248.428.5
Interest coverage
-107.22-104.74-79.41-257.920
Income quality
0.790.720.930.580.42
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.6315.825.1883.1260.72
Research and developement to revenue
11.6449.1114.48229.57153.97
Intangibles to total assets
00000
Capex to operating cash flow
0.40.270.170.230.24
Capex to revenue
-4.41-12.03-2.9-45.45-22.06
Capex to depreciation
-3.54-2.21-1.72-1.39-0.97
Stock based compensation to revenue
1.255.242.2133.1826.88
Graham number
8.248.047.537.276.76
ROIC
-0.08-0.09-0.09-0.11-0.12
Return on tangible assets
-0.06-0.07-0.07-0.08-0.08
Graham Net
3.012.291.24-0.22-0.14
Working capital
334.73M289.9M228.25M142.12M153.27M
Tangible asset value
330.21M302.74M277.18M247.57M219.23M
Net current asset value
180.1M135.92M76.88M-8.31M-4.62M
Invested capital
0.140.160.190.170.22
Average receivables
324K572K1.12M1.59M1.69M
Average payables
4.87M5.57M4.46M3.55M4.78M
Average inventory
00-732.5K-1.59M-1.69M
Days sales outstanding
14.73134.7476.661.55K1.01K
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
6.110.671.170.060.09
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.1-0.11-0.13-0.15
Capex per share
-0.17-0.11-0.09-0.08-0.05

IPSC Frequently Asked Questions

What is Century Therapeutics, Inc. stock symbol ?

Century Therapeutics, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol IPSC

Is Century Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $21.25. The lowest prediction is $14 and the highest is $27

What is IPSC stock prediction ?

What is Century Therapeutics, Inc. stock quote today ?

Century Therapeutics, Inc. stock price is $2.38 today.

Is Century Therapeutics, Inc. stock public?

Yes, Century Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Similar Market Cap